Mirati’s First KRAS Data Look At Least As Good As Amgen’s

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The small biotech firm has traded higher in recent months based on Amgen’s AMG 510 results to date, and saw its share price soar based on initial efficacy data for MRTX849 in lung and colorectal cancers. 

SC1910_Tree-lungs_246277042_1200.jpg
KRAS G12C mutations are found in 14% of non-small cell lung cancer tumors • Source: Shutterstock

Mirati Therapeutics Inc.’s first-in-human results for the KRAS G12C inhibitor MRTX849 appear to be at least as good as data disclosed to date for Amgen Inc.’s similarly targeted AMG 510 in lung and colorectal cancer patients with KRAS-expressing tumors that have G12C mutations, according to data presented on 28 October at an early stage research meeting hosted by the American Association for Cancer Research, the National Cancer Institute and the European Organisation for Research and Treatment of Cancer. 

Mirati’s results have been closely watched because MRTX849 is only the second drug against KRAS to show efficacy in patients...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D